Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: A systematic review
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
PURPOSE: To understand the currently available post-marketing real-world evidence of the incidences of and discontinuations due to the BAEs of irritability, anger, and aggression in people with epilepsy (PWE) treated with the anti-seizure medications (ASMs) brivaracetam (BRV), levetiracetam (LEV), perampanel (PER), and topiramate (TPM), as well as behavioral adverse events (BAEs) in PWE switching from LEV to BRV. METHODS: A systematic review of published literature using the Cochrane Library, PubMed/MEDLINE, and Embase was performed to identify retrospective and prospective observational studies reporting the incidence of irritability, anger, or aggression with BRV, LEV, PER, or TPM in PWE. The incidences of these BAEs and the rates of discontinuation due to each were categorized by ASM, and where possible, weighted means were calculated but not statistically assessed. Behavioral and psychiatric adverse events in PWE switching from LEV to BRV were summarized descriptively. RESULTS: A total of 1500 records were identified in the searches. Of these, 44 published articles reporting 42 studies met the study criteria and were included in the data synthesis, 7 studies were identified in the clinical trial database, and 5 studies included PWE switching from LEV to BRV. Studies included a variety of methods, study populations, and definitions of BAEs. While a wide range of results was reported across studies, weighted mean incidences were 5.6% for BRV, 9.9% for LEV, 12.3% for PER, and 3.1% for TPM for irritability; 3.3%* for BRV, 2.5% for LEV, 2.0% for PER, and 0.2%* for TPM for anger; and 2.5% for BRV, 2.6% for LEV, 4.4% for PER, and 0.5%* for TPM for aggression. Weighted mean discontinuation rates were 0.8%* for BRV, 3.4% for LEV, 3.0% for PER, and 2.2% for TPM for irritability and 0.8%* for BRV, 2.4% for LEV, 9.2% for PER, and 1.2%* for TPM for aggression. There were no discontinuations for anger. Switching from LEV to BRV led to improvement in BAEs in 33.3% to 83.0% of patients (weighted mean, 66.6%). *Denotes only 1 study. CONCLUSIONS: This systematic review characterizes the incidences of irritability, anger, and aggression with BRV, LEV, PER, and TPM, and it provides robust real-world evidence demonstrating that switching from LEV to BRV may improve BAEs. While additional data remain valuable due to differences in methodology (which make comparisons difficult), these results improve understanding of the real-world incidences of discontinuations due to these BAEs in clinical practice and can aid in discussions and treatment decision-making with PWE.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quality of life of people with epilepsy: a European study
Baker, G. A., Jacoby, A., Buck, D., Stalgis, C., & Monnet, D. (1997) · Epilepsia · doi:10.1111/j.1528-1157.1997.tb01128.x · Cited by 847
Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy: A randomized trial
French, J. A., Krauss, G. L., Wechsler, R. T., Wang, X.-F., DiVentura, B., Brandt, C., Trinka, E., O'Brien, T. J., Laurenza, A., Patten, A., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001930 · Cited by 329 · cited 2×
“Data from the phase 3, double-blind, controlled trials of PER reported BAEs associated with hostility/aggressive behavior (‘‘narrow-and-broad” standardized MedDRA queries [SMQ] terms) in 11.8% of patients with focal epilepsy and 18.5% of patients with primary generalized tonicclonic seizures (PGTCS) in idiopathic gene…”
BackgroundInfluentialKlitgaard, H., Matagne, A., Nicolas, J., Gillard, M., Lamberty, Y., De Ryck, M., Kaminski, R. M., Leclercq, K., Niespodziany, I., Wolff, C., et al. (2016) · Epilepsia · doi:10.1111/epi.13340 · Cited by 168
Self-citation
Cited by
Levetiracetam Mechanisms of Action: From Molecules to Systems
Contreras-García, I. J., Cárdenas-Rodríguez, N., Romo-Mancillas, A., Bandala, C., Zamudio, S. R., Gómez-Manzo, S., Hernández-Ochoa, B., Mendoza-Torreblanca, J. G., & Pichardo-Macías, L. A. (2022) · Pharmaceuticals · doi:10.3390/ph15040475 · Cited by 131
“Moreover, Wolking et al. investigated the genetic risk of rare variants for drug response to three AEDs (including LEV treatment for at least 1 year) through an analysis of the sequencing, genotyping, variant selection, and annotation of an epileptic cohort derived from the EpiPGX Consortium, to identify genetic bioma…”
BackgroundInfluentialFukuyama, K., & Okada, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094473 · Cited by 22
“A recent systematic review reported that switching from levetiracetam to brivaracetam could improve adverse behavioural/psychiatric reactions induced by levetiracetam [32].”
BackgroundKlein, P., & Bourikas, D. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02876-z · Cited by 21
“A systematic review of BAEs (irritability, anger, aggression) in patients with epilepsy reported that switching from LEV to BRV led to improvement in BAEs in 33.3–83.0% of patients [66].”
BackgroundInfluentialSelf-citationPresynaptic antiseizure medications-basic mechanisms and clues for their rational combinations
Czapińska-Ciepiela, E. K., Łuszczki, J., Czapiński, P., Czuczwar, S. J., & Lasoń, W. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00603-7 · Cited by 13
“The side effect spectrum consists of irritability and aggres - sion and can be aggravated by psychosis, depression, and suicidal ideation [92].”
Background
Metadata
- Authors
- Steinhoff, B. J., Klein, P., Klitgaard, H., Laloyaux, C., Moseley, B. D., Ricchetti-Masterson, K., Rosenow, F., Sirven, J. I., Smith, B., Stern, J. M., Toledo, M., Zipfel, P. A., & Villanueva, V.
- Venue
- Epilepsy & Behavior
- Publisher
- Elsevier BV
- Published
- 2021-05
- Volume
- 118
- Pages
- 107939
- ISSN
- 1525-5050 (ISSN-L)
- OpenAlex
- W3155449896
- Cited by
- 118
- References
- 3
- FWCI
- 3.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: A systematic review. https://app.cochat.ai/papers/10.1016/j.yebeh.2021.107939
- The paper
- Steinhoff, B. J., Klein, P., Klitgaard, H., Laloyaux, C., Moseley, B. D., Ricchetti-Masterson, K., Rosenow, F., Sirven, J. I., Smith, B., Stern, J. M., Toledo, M., Zipfel, P. A., & Villanueva, V. (2021). Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: A systematic review. Epilepsy & Behavior. https://doi.org/10.1016/j.yebeh.2021.107939
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.